A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 876-885

  Soriano, Aroa ^a   Vendrell, Marc ^a,d   Gonzalez, Sergio ^a   Mallol, Josefa ^a   Albericio, Fernando ^a   Royo, Miriam ^a   Lluís, Carmen ^a   Canela, Enric I ^a   Franco, Rafael ^a,b,c   Cortés, Antoni ^a   Casadó, Vicent ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; INDOLOQUINOLIZIDINE PEPTIDE 28; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; KINETICS; PRIORITY JOURNAL;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ALLOSTERIC REGULATION; BENZAZEPINES; CELL LINE; CYCLIC AMP; DRUG PARTIAL AGONISM; HUMANS; LIGANDS; OLIGOPEPTIDES; QUINOLIZIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 77249153363     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.158824     Document Type: Article

References (38)

1. Andersen PH and Nielsen EB (1991) Novel approaches to development of antipsychotics. Drug News Perspect 4:150-157.
2. Araki KY, Sims JR, and Bhide PG (2007) Dopamine receptors mRNA and protein expression in the mouse corpus striatum and cerebral cortex during pre- and post-natal development. Brain Res 1156:31-45.
3. Bridges TM and Lindsley CW (2008) G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol 3:530-541.
4. Bubenikova-Valesova V, Svoboda J, Horacek J and Vales K (2009) The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats. Int J Neuropsychopharmacol 12:873-883.
5. Cai JX and Arnsten AF (1997) Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther 283:183-189.
6. Casadó V, Cantí C, Mallol J, Canela EI, Lluis C, and Franco R (1990) Solubilization of A1 adenosine receptor from pig brain: characterization and evidence of the role of the cell membrane on the coexistence of high- and low-affinity states. J Neurosci Res 26:461-473.
7. Casadó V, Cortés A, Ciruela F, Mallol J, Ferré S, Lluis C, Canela EI, and Franco R (2007) Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: the receptordimer cooperativity index. Pharmacol Ther 116:343-354.
8. Casadó V, Cortés A, Mallol J, Pérez-Capote K, Ferré S, Lluis C, Franco R, and Canela EI (2009a) GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers?. Pharmacol Ther 124:248-257.
9. Casadó V, Ferrada C, Bonaventura J, Gracia E, Mallol J, Canela EI, Lluís C, Cortés A, and Franco R (2009b) Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist-antagonist binding modulation. Biochem Pharmacol 78:1456-1463.
10. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
11. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
12. Ericksen SS, Cummings DF, Weinstein H, and Schetz JA (2009) Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding. J Pharmacol Exp Ther 328:40-54.
13. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, et al. (2009). Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5:131-134.
14. Franco R, Casadó V, Mallol J, Ferré S, Fuxe K, Cortés A, Ciruela F, Lluis C, and Canela EI (2005) Dimer-based model for heptaspanning membrane receptors. Trends Biochem Sci 30:360-366.
15. Franco R, Casadó V, Mallol J, Ferrada C, Ferré S, Fuxe K, Cortés A, Ciruela F, Lluis C, and Canela EI (2006) The two-state dimer receptor model: a general model for receptor dimers. Mol Pharmacol 69:1905-1912.
16. George SR, Lee SP, Varghese G, Zeman PR, Seeman P, Ng GY, and O'Dowd BF (1998) A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J Biol Chem 273:30244-30248.
17. Gerfen CR (2004) The Rat Nervous System (Paxinos G ed) pp 445-508, Elsevier Academic Press, Amsterdam.
18. Goldman-Rakic PS (1999) The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 46: 650-661.
19. Goldman-Rakic PS, Muly EC III, and Williams GV (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31:295-301.
20. Guo W, Urizar E, Kralikova M, Mobarec JC, Shi L, Filizola M, and Javitch JA (2008) Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J 27:2293-2304.
21. Han Y, Moreira IS, Urizar E, Weinstein H, and Javitch JA (2009) Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 9:688-695.
22. Hoare SR, Coldwell MC, Armstrong D, and Strange PG (2000) Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol 130:1045-1059.
23. Kong MM, Fan T, Varghese G, O'Dowd BF, and George SR (2006) Agonist-induced cell surface trafficking of an intracellularly sequestered D1 dopamine receptor homo-oligomer. Mol Pharmacol 70:78-89.
24. Lidow MS, Wang F, Cao Y, and Goldman-Rakic PS (1998) Layer V neurons bear the majority of mRNA encoding the five distinct dopamine receptors subtypes in the primate prefrontal cortex. Synapse 28:10-20.
25. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
26. Miyamoto S, Duncan GE, Marx CE, and Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104.
27. Neubig RR, Spedding M, Kenakin T, Christopoulos A, and International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
28. Neve KA, Seamans JK, and Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205.
29. Ng GY, Mouillac B, George SR, Caron M, Dennis M, Bouvier M, and O'Dowd BF (1994) Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. Eur J Pharmacol 267:7-19.
30. Sarrió S, Casadó V, Escriche M, Ciruela F, Mallol J, Canela EI, Lluis C, and Franco R (2000) The heat shock cognate protein hsc73 assembles with A(1) adenosine receptors to form functional modules in the cell membrane. Mol Cell Biol 20:5164-5174.
31. Schetz JA (2005) Allosteric modulation of dopamine receptors. Mini Rev Med Chem 5:555-561.
32. Schetz JA and Sibley DR (2001) The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. J Pharmacol Exp Ther 296:359-363.
33. Schwartz TW and Holst B (2006) Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26:107-128.
34. Schwartz TW and Holst B (2007) Allosteric enhancers, allosteric agonists and agoallosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 28:366-373.
35. Sedvall G, Farde L, Hall H, Halldin C, Karlsson P, Nordström AL, Nyberg S, and Pauli S (1995) Utilization of radioligands in schizophrenia research. Clin Neurosci 3:112-121.
36. 2 Dopamine Receptors. ChemMedChem 4:1514-1522.
37. Verma V, Mann A, Costain W, Pontoriero G, Castellano JM, Skoblenick K, Gupta SK, Pristupa Z, Niznik HB, Johnson RL, et al. (2005) Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L- leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther 315:1228-1236.
38. Wu WL, Burnett DA, Spring R, Greenlee WJ, Smith M, Favreau L, Fawzi A, Zhang H, and Lachowicz JE (2005) Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J Med Chem 48:680-693.